INHIBITION OF PRMT5 AS A CANCER THERAPY

Abstract

This proposal is aimed at improving the clinical benefit of BRAF/MEK and CDK4 inhibitors by combining with PRMT5 inhibition and extending these combination therapies into cancers with poor outcomes (pancreatic and oesophageal). These studies will provide mechanistic insight into the action of PRMT5 inhibitors in RAS/RAF/CDK4 driven tumours and identify patients that will likely benefit from PRMT5 therapy including combination therapy.

Related publications (1)

Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?

Lorey K Smith, Shaghayegh Arabi, Emily J Lelliott, Grant A McArthur, Karen E Sheppard

2020-06-01

Excess body weight has been identified as a risk factor for many types of cancers, and for the majority of cancers, it is associat..